NEW YORK, May 22 (Reuters) - Quest Diagnostics Inc shares jumped to a record high on heavy volume on Friday following chatter on Twitter and elsewhere that the lab testing company may be trying to...
NEW YORK, May 22 (Reuters) - Quest Diagnostics Inc shares jumped on heavy volume on Friday following chatter on Twitter and elsewhere that the lab testing company may be trying to sell itself.
We saw few surprises in Quest Diagnostics ' first-quarter results, and we ..... leverage to kick in. We have also left Quest 's narrow moat intact. Even as ..... reference lab market have improved, Quest continues to trail behind LabCorp
Quintiles and Quest Diagnostics announced an agreement on March 31 to form a ..... leaving our fair value estimates for Quintiles and Quest unchanged. Quintiles will own 60% and Quest Diagnostics 40% of the joint venture, and management claims
On March 31, Quintiles and Quest Diagnostics announced an agreement to form a joint ..... fair value estimates for Quintiles and Quest unchanged. Quintiles will own 60% and Quest Diagnostics 40% of the joint venture; management
Quest Diagnostics posted respectable fourth-quarter results ..... liked the structural characteristics of Quest 's narrow moat and anticipate these will ..... Affordable Care Act. Unfortunately, Quest 's improved volume did not translate
for the combined company. However, we believe the combined entity will enjoy competitive benefits over key rival Quest Diagnostics , especially over the longer term as the new post-health-care-reform world evolves. We think the strategic
Quest Diagnostics posted respectable third-quarter results ..... suggest volume and pricing are improving for Quest . We stand behind the firm's narrow ..... the moat trend is stable. We applaud Quest 's decision to walk away from unprofitable
Quest Diagnostics released second-quarter performance ..... organic volume growth remains lackluster at Quest . On one hand, quarterly organic volume ..... quarters of declines. On the other hand, Quest continues to trail its main rival LabCorp
are reimbursed under Medicare and Medicaid respectively. In the U.S., Sonic remains a minnow compared with Quest Diagnostics and LabCorp, with a market share of about 1.5% versus 15%. The U.S. market remains attractive given expected